This study is testing a new medicine called *AR1001*, which might help people in the early stages of Alzheimer’s Disease (AD). Alzheimer's is an illness that affects memory and thinking skills. *Phase 3* means this is a later stage in testing the drug to see how well it works and if it’s safe. The study is *double-blind*, meaning neither the doctors nor the participants know who is getting the real medicine or a placebo (a fake pill that doesn’t do anything). This helps make the results more accurate.

People who can join this study are between the ages of 55 to 90 and have mild memory problems. They must also have someone who knows them well, like a caregiver, to help with the study. People with other health issues or who are pregnant cannot join.

• The study is conducted at multiple locations.
• Participants need to be able to make regular clinic visits.
• Study participation may involve risks, which will be explained during the consent process.